These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 14524733)

  • 1. Oral fludarabine.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(21):2317-23. PubMed ID: 14524733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with fludarabine in leukaemia.
    Keating MJ; Estey E; O'Brien S; Kantarjian H; Robertson LE; Plunkett W
    Drugs; 1994; 47 Suppl 6():39-49. PubMed ID: 7525188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of oral fludarabine in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zhu Y; Qin Q; Xie Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Mar; 38(3):221-4. PubMed ID: 23545817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral fludarabine: a viewpoint by Dieter Huhn.
    Huhn D
    Drugs; 2003; 63(21):2324. PubMed ID: 14524734
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral fludarabine therapy in chronic lymphocytic leukemia--increased convenience.
    Boogaerts MA
    Hematol J; 2004; 5 Suppl 1():S31-7. PubMed ID: 15079151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
    Calvo-Villas JM; Urcuyo BM; Umpierrez AM; Sicilia F
    Onkologie; 2008 Apr; 31(4):197-9. PubMed ID: 18418022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
    Dearden CE; Richards S; Else M; Catovsky D; Hillmen P
    Cancer; 2011 Jun; 117(11):2452-60. PubMed ID: 24048793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia.
    Leporrier M
    Hematol J; 2004; 5 Suppl 1():S10-9. PubMed ID: 15079149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
    Assouline S; Buccheri V; Delmer A; Gaidano G; Trneny M; Berthillon N; Brewster M; Catalani O; Li S; McIntyre C; Sayyed P; Badoux X
    Lancet Haematol; 2016 Mar; 3(3):e128-38. PubMed ID: 26947201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia.
    Bergmann L; Fenchel K; Jahn B; Mitrou PS; Hoelzer D
    Ann Oncol; 1993 May; 4(5):371-5. PubMed ID: 8353071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine: a review of its use in non-Hodgkin's lymphoma.
    Anderson VR; Perry CM
    Drugs; 2007; 67(11):1633-55. PubMed ID: 17661532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral fludarabine: a viewpoint by Bruce D. Cheson.
    Cheson BD
    Drugs; 2003; 63(21):2325. PubMed ID: 14524736
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
    Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM
    J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
    Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine: new indication. First-line treatment of CLL: unconvincing evidence.
    Prescrire Int; 2005 Feb; 14(75):3-5. PubMed ID: 15747447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experience with fludarabine treatment and review of the literature].
    Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
    Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia.
    Boogaerts MA; Van Hoof A; Catovsky D; Kovacs M; Montillo M; Zinzani PL; Binet JL; Feremans W; Marcus R; Bosch F; Verhoef G; Klein M
    J Clin Oncol; 2001 Nov; 19(22):4252-8. PubMed ID: 11709569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
    Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.